| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_23af9dcf337222c94b0ee5d144c3ba04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b32bd4036d9aee50de3527913bf95b9b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bae8261aa0146620917d76a004c2cabd |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F11-3013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F11-3457
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F11-3636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F11-3476
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F11-366
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F11-261 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 |
| filingDate |
2010-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17a1a957d7c61132c98cf10f9c2de39f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03f3ebea917bedb4c51db45d8f0a018f |
| publicationDate |
2010-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010102031-A2 |
| titleOfInvention |
Methods for treating ocular inflammatory diseases |
| abstract |
A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022180568-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8900626-B2 |
| priorityDate |
2009-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |